Axsome Therapeutics’ AXSM shares have rallied 19.4% in the past month against the industry’s decrease of 0.2%, driven by ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at ...

Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report issued ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Perspective Therapeutics (CATX – Research ...

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...

Axsome Therapeutics, Inc. NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...